1. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
- Author
-
Caroline M. Hsu, Daniel E. Weiner, Harold J. Manley, Gideon N. Aweh, Vladimir Ladik, Jill Frament, Dana Miskulin, Christos Argyropoulos, Kenneth Abreo, Andrew Chin, Reginald Gladish, Loay Salman, Doug Johnson, and Eduardo K. Lacson
- Subjects
Male ,COVID-19 Vaccines ,Time Factors ,Epidemiology ,Vaccine Efficacy ,Critical Care and Intensive Care Medicine ,Antibodies, Viral ,Immunocompromised Host ,Immunogenicity, Vaccine ,Renal Dialysis ,Humans ,Renal Insufficiency, Chronic ,BNT162 Vaccine ,Aged ,Retrospective Studies ,Aged, 80 and over ,Transplantation ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Middle Aged ,United States ,Treatment Outcome ,Nephrology ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,Female ,Original Article ,Biomarkers ,2019-nCoV Vaccine mRNA-1273 - Abstract
BACKGROUND AND OBJECTIVES: Although most patients receiving maintenance dialysis exhibit initial seroresponse to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, concerns exist regarding the durability of this antibody response. This study evaluated seroresponse over time. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study included patients on maintenance dialysis, from a midsize national dialysis provider, who received a complete SARS-CoV-2 vaccine series and had at least one antibody titer checked after full vaccination. IgG spike antibodies (anti-spike IgG) titers were assessed monthly with routine laboratory tests after vaccination; the semiquantitative assay reported a range between zero and ≥20 Index. Descriptive analyses compared trends over time by history of coronavirus disease 2019 (COVID-19) and vaccine type. Time-to-event analyses examined the outcome of loss of seroresponse (anti-spike IgG
- Published
- 2021